- 24 h
- 7 Tage
- 14 Tage
- 6 Monate
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:10 | Sino Biopharm targets 30 innovative products by 2027 | - | China Daily | ||
| 07:36 | CIC Market Solutions Initiates Buy Coverage of ABIONYX Pharma | 134 | Business Wire | Regulatory News:
ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), next-generation biopharma dedicated to the development of innovative biomedicines based on recombinant apolipoprotein apoA-I... ► Artikel lesen | |
| 07:15 | Dividendenbekanntmachungen (21.03.2025) | 264 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ARTHUR J GALLAGHER & CO US3635761097 0,65 USD EUR ASX LIMITED AU000000ASX7 1,112 AUD EUR BANK OF THE JAMES FINANCIAL GROUP INC US4702991088 0... ► Artikel lesen | |
| 07:15 | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma gibt Finanzzahlen bekannt und berichtet über erfolgreichen Geschäftsverlauf 2024 | 264 | EQS Group (DE) | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Jahresbericht
Heidelberg Pharma gibt Finanzzahlen bekannt und berichtet über erfolgreichen Geschäftsverlauf 2024
21.03.2025... ► Artikel lesen | |
| 07:15 | CureVac Aktie: Bemerkenswerter Aufschwung! | 236 | Börse Global | Der Tübinger Impfstoffhersteller meldet beeindruckendes Quartalsergebnis mit 542,57 Millionen USD Umsatz, während die Aktie zwischen 2,06 und 4,98 EUR schwankt. Die CureVac-Aktie zeigte am Donnerstag... ► Artikel lesen | |
| 06:26 | Atai Life Sciences setzt auf Bitcoin als Teil der Finanzstrategie | 3 | IT BOLTWISE | ||
| 06:18 | Armata Pharmaceuticals GAAP EPS of -$0.23, revenue of $1.2M | 1 | Seeking Alpha | ||
| 06:18 | vTv Therapeutics GAAP EPS of -$0.55, revenue of $0.02M | 2 | Seeking Alpha | ||
| 05:15 | Heidelberg Pharma Aktie: Positive Signale aus dem Management! | 337 | Börse Global | Heidelberg Pharma erhält durch eine modifizierte Lizenzvereinbarung mit HealthCare Royalty (HCRx) eine sofortige Zahlung von 20 Millionen US-Dollar. Diese strategische Anpassung stärkt die finanzielle... ► Artikel lesen | |
| 04:17 | Nomura Cuts SINO BIOPHARM TP to $5.52 on Double-digit Growth Guidance for 2025 | 4 | AASTOCKS | ||
| 03:12 | TELA Bio sees 23-27% revenue growth for 2025 with expanded sales strategy | 2 | Seeking Alpha | ||
| 03:10 | Friday's HotCopper Trends: Telix bags FDA approval, Paladin's mine drenched | March 21, 2025 | 5 | The Market Herald Australia | ||
| 02:58 | Sino Biopharmaceutical Limited: Sino Biopharm (1177.HK) Announces 2024 Annual Results | 208 | JCN Newswire | - Dual Success of Innovative Drugs and Generic Drugs- Revenue Recorded RMB28.87 Billion- Adjusted non-HKFRS Profit Attributable to the Owners of the Parent Recorded RMB3.46 BillionHONG KONG, Mar 20... ► Artikel lesen | |
| 01:06 | Valneva outlines €170M-€180M sales target for 2025 with focus on IXCHIQ and Lyme vaccine developments | 37 | Seeking Alpha | ||
| 00:42 | Arcadia Biosciences outlines 2025 growth potential for Zola after 46% sales increase in 2024 | 1 | Seeking Alpha | ||
| 00:42 | Cibus outlines advanced gene editing initiatives with potential revenue milestones by 2026 | 1 | Seeking Alpha | ||
| 00:35 | Telix shares slip 11% from highs. Time to buy this high flying biotech? | 9 | The Motley Fool Australia | ||
| 00:30 | BIOXYNE LIMITED: Proposed issue of securities - BXN | 1 | ASX | ||
| 00:30 | BIOXYNE LIMITED: Proposed issue of securities - BXN | 2 | ASX | ||
| 00:30 | BIOXYNE LIMITED: Proposed issue of securities - BXN | 1 | ASX |
Seite:
1 2 3 4 5 Weiter >>
- 24 h
- 7 Tage
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| AUTOLUS THERAPEUTICS | 10 | - | +1,29 % | Autolus Therapeutics plc: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates | AUCATZYL® (obecabtagene autoleucel) U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA... ► Artikel lesen | ||
| IMMUNEERING | 9 | - | -1,20 % | Immuneering Corporation: Immuneering Names Dr. Igor Matushansky as Chief Medical Officer | Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from... ► Artikel lesen | ||
| NIOX GROUP | 8 | 2 | +33,07 % | AIM Market Roundup: Priority Intelligence, Niox, Coral Products | |||
| DYNE THERAPEUTICS | 8 | - | -0,20 % | Dyne Therapeutics Names Erick Lucera As CFO | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases... ► Artikel lesen | ||
| ARS PHARMACEUTICALS | 8 | - | 0,00 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen | ||
| MONTE ROSA THERAPEUTICS | 7 | 21 | +4,33 % | Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders | |||
| VALNEVA | 6 | 5 | -1,01 % | Valneva will Cashburn 2025 deutlich reduzieren | Valneva hat für das Geschäftsjahr 2024 einen Nettoverlust von 12,2 Millionen Euro gemeldet, nachdem im Vorjahr noch ein Minus von 101,4 Millionen Euro angefallen war. Die deutliche Reduktion resultierte... ► Artikel lesen | ||
| ABEONA THERAPEUTICS | 6 | 5 | +1,27 % | Abeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans | FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025 Launch preparations on track toward goal... ► Artikel lesen | ||
| SIONNA THERAPEUTICS | 6 | - | -2,11 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results | Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline... ► Artikel lesen | ||
| COGNITION THERAPEUTICS | 5 | 4 | 0,00 % | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update | Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB) Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified... ► Artikel lesen |
- Alle
| Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
|---|---|---|---|---|---|---|---|---|---|
| BIO-GATE AG | 0,720 | 3,40 | +372 % | 1 | - | - | |||
| EVOTEC SE | 6,475 | 9 | +39 % | 1 | - | 1 | |||
| QIAGEN NV | 36,335 | 48 | +32 % | 4 | 1 | - | |||
| BIONTECH SE ADR | 89,55 | 118,03 | +32 % | 5 | 3 | - | |||
| SARTORIUS STEDIM BIOTECH SA | 192,05 | 247,20 | +29 % | 6 | 2 | - |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
